Enhancement of Impaired Olfactory Neural Activation and Cognitive Capacity by Liraglutide, but Not Dapagliflozin or Acarbose, in Patients With Type 2 Diabetes: A 16-Week Randomized Parallel Comparative Study.
Objective: The comparative neuroprotective effects of different antidiabetes drugs have not been characterized in randomized controlled trials. Here, we investigated the therapeutic effects of liraglutide, dapagliflozin, or acarbose treatment on brain functional alterations and cognitive changes in...
| Published in: | Diabetes Care Vol. 45; no. 5; pp. 1201 - 1211 |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | diagnostic images research tables/charts randomized controlled trial Journal Article |
| Published: |
American Diabetes Association
May2022
|
| Online Access: | View this record in EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=157213966&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 157213966 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 01495992 1G7 jtl: Diabetes Care issn: 01495992 maglogo: N pubinfo: dt: May2022 vid: 45 iid: 5 pid: 1367 pub: American Diabetes Association place: Arlington, Virginia artinfo: ui: 157213966 157213966 NLM35263425 157213966 10.2337/dc21-2064 NLM35263425 157213966 ppf: 1201 ppct: 10 formats: tig: atl: Enhancement of Impaired Olfactory Neural Activation and Cognitive Capacity by Liraglutide, but Not Dapagliflozin or Acarbose, in Patients With Type 2 Diabetes: A 16-Week Randomized Parallel Comparative Study. aug: au: Cheng, Haiyan Zhang, Zhou Zhang, Bing Zhang, Wen Wang, Jin Ni, Wenyu Miao, Yingwen Liu, Jiani Bi, Yan sug: subj: Metformin Therapeutic Use Diabetes Mellitus, Type 2 Drug Therapy Benzhydryl Compounds Hypoglycemic Agents Therapeutic Use Human Blood Glucose Metabolism Glycosides Acarbose Therapeutic Use Cognition Comparative Studies Multicenter Studies Randomized Controlled Trials Evaluation Research Validation Studies ab: Objective: The comparative neuroprotective effects of different antidiabetes drugs have not been characterized in randomized controlled trials. Here, we investigated the therapeutic effects of liraglutide, dapagliflozin, or acarbose treatment on brain functional alterations and cognitive changes in patients with type 2 diabetes.Research Design and Methods: Thirty-six patients with type 2 diabetes inadequately controlled with metformin monotherapy were randomized to receive liraglutide, dapagliflozin, or acarbose treatment for 16 weeks. Brain functional MRI (fMRI) scan and a battery of cognitive assessments were evaluated pre- and postintervention in all subjects.Results: The 16-week treatment with liraglutide significantly enhanced the impaired odor-induced left hippocampal activation with Gaussian random field correction and improved cognitive subdomains of delayed memory, attention, and executive function (all P < 0.05), whereas dapagliflozin or acarbose did not. Structural equation modeling analysis demonstrated that such improvements of brain health and cognitive function could be partly ascribed to a direct effect of liraglutide on left hippocampal activation (β = 0.330, P = 0.022) and delayed memory (β = 0.410, P = 0.004) as well as to the metabolic ameliorations of reduced waist circumference, decreased body fat ratio, and elevated fasting insulin (all P < 0.05).Conclusions: Our head-to-head study demonstrated that liraglutide enhanced impaired brain activation and restored impaired cognitive domains in patients with type 2 diabetes, whereas dapagliflozin and acarbose did not. The results expand the clinical application of liraglutide and provide a novel treatment strategy for individuals with diabetes and a high risk of cognitive decline. pubtype: Academic Journal doctype: diagnostic images research tables/charts randomized controlled trial Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|